Drug Profile
Research programme: metabotropic glutamate receptor modulators - Johnson & Johnson
Alternative Names: VU0364289Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Class Piperazines
- Mechanism of Action Metabotropic glutamate receptor 5 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in USA